Terms: = Prostate cancer AND P2RY8, RP11-261P4_4, 286530, ENSG00000182162, MGC50878, P2Y8, Q86VZ1 AND Staging
1392 results:
1. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
[TBL] [Abstract] [Full Text] [Related]
2. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract] [Full Text] [Related]
3. A pictorial view on false positive findings of
Dancheva Z; Chausheva S; Stoeva T; Dyankova M; Yordanova T; Chaushev B; Marinov R; Nikolov V; Abushev P; Todorov G; Dimitrova E; Klisarova A; Anakievski D
Hell J Nucl Med; 2024; 27(1):16-26. PubMed ID: 38629815
[TBL] [Abstract] [Full Text] [Related]
4. Is Unilateral Lymphadenectomy an Option in Selected Patients with prostate cancer?
Kassab BN; De Pablos-Rodríguez P; Ferrer ÁG; García AC; Fons AC; Aragón F; Ramón-Borja JC; Ramírez-Backhaus M
Arch Esp Urol; 2024 Mar; 77(2):129-134. PubMed ID: 38583004
[TBL] [Abstract] [Full Text] [Related]
5. Optimizing PSMA scintigraphy for resource limited settings - a retrospective comparative study.
Kolade OU; Brink A; Ayeni AO; More S; Holness J
Cancer Imaging; 2024 Apr; 24(1):46. PubMed ID: 38556864
[TBL] [Abstract] [Full Text] [Related]
6. Extended pelvic lymph node dissection during robotic prostatectomy: antegrade versus retrograde technique.
Albo G; Gallioli A; Ripa F; De Lorenzis E; Boeri L; Bebi C; Rocchini L; Longo F; Zanetti SP; Turetti M; Piccoli M; Montanari E
BMC Urol; 2024 Mar; 24(1):64. PubMed ID: 38515053
[TBL] [Abstract] [Full Text] [Related]
7. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive prostate cancer and Survival.
Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
[TBL] [Abstract] [Full Text] [Related]
8. Development of a prognostic model for long-term survival of young patients with bladder cancer: a retrospective analysis of the SEER Database.
Guo L; Liu L; Liu Y; Yang T; Wang G; Liu J; Li S; Cai J
BMJ Open; 2024 Mar; 14(3):e080092. PubMed ID: 38458812
[TBL] [Abstract] [Full Text] [Related]
9. Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use criteria in a large network system.
Bennett R; Li EV; Ho AY; Aguiar JA; Neill C; Rowe SP; Patel HD; Savas H; Ross AE
Prostate; 2024 Jun; 84(8):717-722. PubMed ID: 38450787
[TBL] [Abstract] [Full Text] [Related]
10. [
Li B; Ding X; Duan L; Shi J; Tang M; Zhang J; Zhao Z; Wu X; Gao Y
Front Endocrinol (Lausanne); 2024; 15():1326858. PubMed ID: 38449842
[TBL] [Abstract] [Full Text] [Related]
11. prostate-Specific Membrane Antigen PET/CT Detection of prostate cancer Metastasis to Thyroid and Cricoid Cartilages.
Eichhorn J; Nelson N; Raichandani S; Sesler A; Palot Manzil FF
Clin Nucl Med; 2024 May; 49(5):481-483. PubMed ID: 38389203
[TBL] [Abstract] [Full Text] [Related]
12. Ductal prostate cancer staging: Role of PSMA PET/CT.
Pepe P; Pepe L; Curduman M; Pennisi M; Fraggetta F
Arch Ital Urol Androl; 2024 Feb; 96(1):12132. PubMed ID: 38363231
[TBL] [Abstract] [Full Text] [Related]
13. Role of PSMA-targeted PET-CT in renal cell carcinoma: a systematic review and meta-analysis.
Singhal T; Singh P; Parida GK; Agrawal K
Ann Nucl Med; 2024 Mar; 38(3):176-187. PubMed ID: 38340144
[TBL] [Abstract] [Full Text] [Related]
14. The Ability of the STAR-CAP staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial Treatment of M0 prostate cancer.
Sung D; Schmidt B; Tward JD
Clin Genitourin Cancer; 2024 Apr; 22(2):426-433.e5. PubMed ID: 38290900
[TBL] [Abstract] [Full Text] [Related]
15. Contribution of 68 Ga-DOTA-FAPI-04 PET/CT to prostate cancer Imaging : Complementary Role in PSMA-Negative Cases.
Ergül N; Çermik TF; Alçın G; Arslan E; Erol Fenercioğlu Ö; Beyhan E; Şahin R; Baloğlu MC; Baykal Koca S; Türkay R; Yücetaş U
Clin Nucl Med; 2024 Mar; 49(3):e105-e110. PubMed ID: 38271254
[TBL] [Abstract] [Full Text] [Related]
16. prostate cancer Risk Stratification by Simple Scoring of the Current pT3 Lesions: A Proposal for a New Pathologic T-staging System.
Miyamoto H; Teramoto Y; Numbere N; Wang Y; Joseph JV
Mod Pathol; 2024 Mar; 37(3):100429. PubMed ID: 38266919
[TBL] [Abstract] [Full Text] [Related]
17. Clinical value of 18F-PSMA-1007 PET/MRI in primary staging of patients with intermediate- to high-risk prostate cancer.
Ali I; Rezk M; Hamouda D; Talaat O; Omar Y; Abdel Tawab M; Nasr I
Br J Radiol; 2024 Feb; 97(1155):622-631. PubMed ID: 38265254
[TBL] [Abstract] [Full Text] [Related]
18. Size of lymph-node metastases in prostate cancer patients undergoing radical prostatectomy: implication for imaging and oncologic follow-up of 2705 lymph-node positive patients.
Falkenbach F; Kachanov M; Leyh-Bannurah SR; Maurer T; Knipper S; Köhler D; Graefen M; Sauter G; Budäus L
World J Urol; 2024 Jan; 42(1):38. PubMed ID: 38244095
[TBL] [Abstract] [Full Text] [Related]
19. Combination of [
Kim J; Lee S; Kim D; Kim HJ; Oh KT; Kim SJ; Choi YD; Giesel FL; Kopka K; Hoepping A; Lee M; Yun M
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1763-1772. PubMed ID: 38200396
[TBL] [Abstract] [Full Text] [Related]
20. Fewer systematic prostate core biopsies in clinical stage T1c prostate cancer leads to biochemical recurrence after brachytherapy as monotherapy.
Ozawa Y; Nohara S; Nakamura K; Hattori S; Yagi Y; Nishiyama T; Yorozu A; Monma T; Saito S
Prostate; 2024 Apr; 84(5):502-510. PubMed ID: 38173289
[TBL] [Abstract] [Full Text] [Related]
[Next]
